Antimicrobial offers improved safety and tolerability


Trichomoniasis is a sexually transmitted disease with potentially serious sequelae. Fortunately, clinicians will soon be able to offer patients with this condition a new molecular entity. The FDA recently approved tinidazole (Tindamax, Presutti Laboratories) for the treatment of trichomoniasis caused by Trichomonas vaginalis in both female and male patients; giardiasis caused by Giardia duodenalis (also called G. lamblia) in both adults and pediatric patients older than three years of age; and amebiasis and amebic liver abscess caused by Entamoeba histolytica in adults and children older than three years of age. Tinidazole will be available in pharmacies sometime this month

Related Content
© 2024 MJH Life Sciences

All rights reserved.